Regeneron announces positive initial results for multiple myeloma drug
From Zacks Investment Research: 2025-05-23 17:24:00
Regeneron Pharmaceuticals, Inc. announced positive initial results from a study on oncology drug linvoseltamab for relapsed/refractory multiple myeloma. High response rates were observed with the drug in combination with carfilzomib or bortezomib. REGN shares have declined 17.3% year to date. The European Commission granted conditional approval for linvoseltamab to treat R/R MM. The FDA is reviewing the BLA with a target action date of July 10, 2025. REGN is focusing on strengthening its oncology portfolio. Eylea sales are declining due to competition from Roche’s Vabysmo. REGN holds a Zacks Rank #3, while Novartis and Pfizer are better-ranked with a Zacks Rank #2. 1. The stock market reached record highs today, with the S&P 500 closing at an all-time high of 4,200 points. Investors are optimistic about the economic recovery and strong corporate earnings reports.
2. A new study found that wearing two masks can significantly reduce the risk of COVID-19 transmission. Researchers at the CDC discovered that double masking can block over 90% of respiratory droplets.
3. The United Nations reported that global carbon dioxide levels have reached a record high, with concentrations exceeding 419 parts per million. This alarming increase is attributed to human activities such as burning fossil fuels and deforestation.
4. In sports news, the Los Angeles Lakers secured a spot in the NBA playoffs after defeating the Golden State Warriors in a thrilling play-in game. LeBron James led the team to victory with a game-winning shot in overtime.
5. NASA successfully launched its Mars helicopter, Ingenuity, on its maiden flight on the red planet. The historic flight marked the first time a powered, controlled aircraft has flown on another planet, demonstrating the potential for future aerial exploration of Mars.
Read more at Zacks Investment Research: Regeneron Initial Data on Multiple Myeloma Drug Encouraging – May 23, 2025